



Biotech Daily

Tuesday January 24, 2017

Daily news on ASX-listed biotechnology companies

- * **ASX UP, BIOTECH EVEN: VIRALYTICS UP 12%; BIONOMICS, IDT DOWN 5%**
- * **RESMED H1 REVENUE UP 15% TO \$1.3b, PROFIT DOWN 14% TO \$202m**
- * **UNIVERSAL BIO RECEIPTS UP 28% TO \$22m, LOSS TO \$1m PROFIT**
- * **OVENTUS PILOT STUDY BACKS O2VENT T FOR CPAP**
- * **AUSTRALIAN ETHICAL TAKES MORE PROFIT BELOW 5% OF INNATE**
- * **HOCKINGS TAKE 31% OF PHYLOGICA**
- * **SUDA REQUESTS HC BERLIN PHARMA SETTLEMENT TRADING HALT**

MARKET REPORT

The Australian stock market climbed 0.7 percent on Tuesday January 24, 2017 with the ASX200 up 39.1 points to 5,650.1 points.

Fourteen of the Biotech Daily Top 40 stocks were up, 14 fell, nine traded unchanged and three were untraded. All three Big Caps were up.

Viralytics was the best, up 12.5 cents or 11.9 percent to \$1.175 with 157,495 shares traded.

Neuren climbed 8.2 percent; Cellmid and Resmed were up more than seven percent; Osprey and Universal Biosensors were up more than six percent; Admedus and Pro Medicus rose more than two percent; Actinogen, Atcor, Cochlear, Compumedics, Nanosonics and Orthocell were up one percent or more; with CSL, Opthea and Sirtex up by less than one percent.

Yesterday's best, Bionomics, led the falls with IDT, both down 5.26 percent to 36 cents and 18 cents respectively, with 309,555 shares and 61,000 shares traded, respectively.

Psivida lost 5.2 percent; Genetic Signatures and Medical Developments fell more than four percent; Benitec and Polynovo were down more than three percent; Mesoblast and Prima shed more than two percent; Prana and Starpharma were down more than one percent; with Clinuvel, Ellex and Impedimed down by less than one percent.

RESMED

Resmed says revenue for the six months to December 31, 2016 was up 15.0 percent to \$US995,846,000 (\$A1,314,097,570) with net profit after tax down 14.4 percent to \$US152,849,000 (\$A201,696,350).

Resmed declared a three-month dividend of 33 US cents a share, for a record date of February 9, payable on March 16, 2017 and said that diluted earnings per share fell 14.3 percent to \$US1.08, with cash and cash equivalents of \$US788,146,000 at December 31, 2016, compared to \$US731,434,000 at June 30, 2016.

Resmed was up 60 cents or 7.2 percent to \$8.92 with 7.7 million shares traded.

UNIVERSAL BIOSENSORS

Universal Biosensors says customer receipts for the year to December 31, 2016 were up 27.8 percent to \$22,433,000, taking last year's loss to an unaudited \$1 million profit.

Last year, Universal Biosensors said revenue for the 12 months to December 31, 2015 was up 76.0 percent to \$16,774,978, reducing its net loss after tax 29.4 percent to \$6,576,416. (BD: Feb 17, 2016).

Today, the company said that service fees generated from Johnson & Johnson's Lifescan Onetouch Verio glucose test strips were up 39.1 percent to \$17,850,000.

Universal Biosensors said that it had \$20,402,000 in cash at December 31, 2016, compared to \$14,350,307 the previous year and it qualified for the Federal Government Research and Development Tax Incentive.

Universal Biosensors said it sold 300,000 Xprecia Stride PT-INR test strips to Siemens for its blood coagulation diagnostic in 2016, but did not state the value of the sales and said that so far in 2017 it had an order for 800,000 more strips from Siemens Healthcare.

Universal Biosensors was up two cents or 6.7 percent to 32 cents.

OVENTUS MEDICAL

Oventus says a four-patient pilot trial of its O2Vent T shows that it reduces the number of respiratory events and pressure swings at the back of the mouth.

Oventus said the O2Vent T reduced respiratory events 78.4 percent, reduced pressure swings at the back of the mouth to similar levels as continuous positive airways pressure (CPAP) and was effective in the presence of high nasal resistance or nasal obstruction. The company said that the O2Vent T could be used as an alternative to as a CPAP either as a standalone appliance, or in combination with CPAP using it as a strapless interface. Oventus said that when the O2 Vent T was used as a CPAP interface, pressure requirements were reduced by about 66 percent and the appliance provided a stable airway at low pressure without the need for a mask.

The company said the design of the CPAP connection enabled simultaneous nasal CPAP delivery, while patients continued to breathe through the device airway, which would benefit "the large percentage of mouth breathing patients that cannot tolerate CPAP".

Oventus said that the trial would to confirm the initial findings in a larger cohort.

Oventus clinical director Dr Chris Hart said "the results show that when there is a switch to breathing through the O2Vent device airway, negative pressure swings were reduced, thus reducing the likelihood of airway collapse which causes obstructive sleep apnoea".

"We look forward to gathering more clinical evidence to validate the O2Vent T as a viable alternative to CPAP and the further development of a strapless low pressure CPAP system for patients with very severe sleep apnoea," Dr Hart said.

Oventus was up four cents or 5.6 percent to 75 cents.

[INNATE IMMUNOTHERAPEUTICS](#)

Australian Ethical Investment says it has further reduced its substantial shareholding in Innate from 11,726,848 shares (5.28%) to 10,826,848 shares (4.87%).

Australian Ethical said it sold 900,000 shares between January 19 and 23, 2017 for \$1,410,836 or \$1.57 a share.

In July, Australian Ethical bought and sold shares in Innate, with the largest acquisitions 4,503,867 shares for \$1,125,967 or 25 cents a share (BD: Jul 21, 2016).

It was widely reported in January that people associated with US President Donald Trump had shares in the company, including major shareholder US Republican Representative Chris Collins, who has been a director of Innate since 2006.

Innate was up three cents or 1.8 percent to 1.71 with 656,622 shares traded.

[PHYLOGICA](#)

Dr Bernard and Dianne Hockings have increased their substantial shareholding in Phylogica from 568,933,332 shares (28.39%) to 615,924,185 shares (30.73%).

The substantial shareholder notice said that BEF and DC Hockings bought shares between October 7, 2016 and January 23, 2017 at "various" prices but did not detail the value as required under the Corporations Act 2001.

The substantial shareholder notice said the shares were also held by daughter Alexandra Hockings and son James Hockings.

In 2014, Phylogica appointed cardiologist Dr Hockings as a director (BD: Jan 24, 2014).

Phylogica was up 0.2 cents or 6.25 percent to 3.4 cents with 3.2 million shares traded.

[SUDA](#)

Suda has requested a trading halt pending an announcement "in relation to the settlement with the estate of HC Berlin Pharma".

Trading will resume on January 27, 2017 or on an earlier announcement.

Last year, Suda said it had received a \$6.15 million statement of claim in relation to a lawsuit against HC Berlin Pharma AG, in liquidation, which it rejected (BD: Jun 3, 2016).

Suda last traded at 2.3 cents.